R&D Trends

Catalent Biologics, Zumutor collaborate to enhanced antibodies

Thursday, August 11, 2016

Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Zumutor Biologics, a developer of biosimilars, novel biobetters and New Biological Entities, have announced a successful research study, combining Catalent’s proprietary GPEx technology and Zumutor’s fucose knockout platform, to create new and more efficacious antibodies.

[Read More]

Juno partners Memorial Sloan Kettering and Eureka Therapeutics

Tuesday, August 9, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has entered into an exclusive license agreement with Memorial Sloan-Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.

[Read More]

Regeneron, Adicet Bio collaborate on immune cell therapeutics

Wednesday, August 3, 2016

Regeneron Pharmaceuticals and Adicet Bio have announced a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics. The companies plan to engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens in order to enable the precise engagement and killing of tumor cells. The collaboration is intended to generate multiple clinical product candidates for various hematological and solid tumor cancers.

[Read More]

Altimmune receives $120M BARDA contract for Anthrax vaccine candidate Nasoshield

Wednesday, August 3, 2016

Altimmune, a clinical stage immunotherapeutic company, was awarded a contract valued at up to $120.2 million over five years from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund the clinical development of NasoShield, its first-in-class anthrax vaccine candidate. Under BARDA contract HHSO100201600008C, Altimmune has been awarded $14.3 million under the base contract to fund its phase I trial for NasoShield, and options to receive up to an additional $105.9 million to fund further preclinical, clinical and manufacturing development activities. 

[Read More]